The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.

The present invention relates to a stable and readily usable administration type including a composition including mesenchymal stem cells cultured in hydrogel, more specifically, a adipose tissue-derived mesenchymal stem cell-hydrogel composition and a method of preparing the same. More specifically, the present invention relates to a composition including mesenchymal stem cells cultured in hydrogel, washed, and filled into a syringe, wherein the composition of the present invention may be readily administered without modification and may not need an enzyme treatment in a final process of preparing transplanted cells, almost no cell is lost because the composition is washed as hydrogel without an washing process using centrifugation or other methods, and the therapeutic effect is shown immediately after administration to an individual because bioactive substances are patched in pores of the hydrogel.

The present invention relates to a stable and readily usable administration type including a composition including mesenchymal stem cells cultured in hydrogel, more specifically, a adipose tissue-derived mesenchymal stem cell-hydrogel composition and a method of preparing the same. More specifically, the present invention relates to a composition including mesenchymal stem cells cultured in hydrogel, washed, and filled into a syringe, wherein the composition of the present invention may be readily administered without modification and may not need an enzyme treatment in a final process of preparing transplanted cells, almost no cell is lost because the composition is washed as hydrogel without an washing process using centrifugation or other methods, and the therapeutic effect is shown immediately after administration to an individual because bioactive substances are patched in pores of the hydrogel.

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.

A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

The present subject matter is directed to a method of manufacturing and purifying an intravenous injection of prothrombin complex concentration (PCC) from plasma Fraction III and a method of manufacturing and purifying an intravenous injection of non-PCC from plasma Fraction IV. The intravenous injection of PCC and non-PCC obtained from the method can be administered to a patient in need thereof for stopping replication, killing and preventing HIV-1 and HIV-2 in a patient.

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

A system for dispensing a biocompatible reactive formulation includes a first chamber containing a first fluid having a first reactive component, a second chamber containing a second fluid having a second reactive component, and a third chamber containing a third fluid. A spray tip assembly is configured for spraying a final mixture of the first, second and third fluids. The spray tip assembly has a spray tip housing, a mixing element disposed within the spray tip housing, a mixing chamber located between the mixing element and an inner surface of the spray tip housing. The mixing element has a proximal end adjacent the proximal end of the spray tip housing and a distal end adjacent the distal end of the spray tip housing, a third fluid inlet opening at the proximal end of the mixing element, and one or more third fluid exit openings formed in the outer surface of the mixing element that are in fluid communication with the third fluid inlet opening and that extend laterally to the outer surface of the mixing element for being in fluid communication with the mixing chamber. A fluid connector is secured to the proximal end of the spray tip housing and opposes the proximal end of the mixing element. The fluid connector has first and second fluid channels in fluid communication with the mixing chamber, and a third fluid channel in fluid communication with the third fluid inlet opening of the mixing element. A pump assembly is coupled with the first, second and third chambers for simultaneously forcing the first, second and third fluids to flow through the first, second and third fluid channels of the fluid connector and into the proximal end of the spray tip housing.